Acacia Pharma

Overview
Price performance
Financials
Research
Thematics

Edison Investment Research is terminating coverage on Acacia Pharma. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

Healthcare |
Update

02.07.21

Acacia Pharma — Progressing on all-important formulary wins

Healthcare |
Update

01.04.21

Acacia Pharma — BARHEMSYS and BYFAVO launched in the US

Healthcare |
Update

21.08.20

Acacia Pharma — Two US drug launches in 2020

Healthcare |
Update

06.07.20

Acacia Pharma — BYFAVO receives FDA approval

Visit Website

Sector

Healthcare

Share Price Performance

Financials

Acacia Pharma has updated the market on the significant ongoing progress of US formulary wins for BARHEMSYS for the treatment and prevention of post-operative nausea and vomiting (PONV) and BYFAVO, an intravenous sedative for use during invasive medical procedures. Formulary access is key for initial sales in the hospital setting and early BARHEMSYS sales should start to trickle through by end FY21/early FY22, while the focus for BYFAVO remains on formulary wins. Obtaining wide formulary adoption is critical and should translate to significant revenue generation from FY22 and maiden operating profit from FY23. Our valuation of Acacia Pharma is unchanged at €1,278m.